None
Quote | Kezar Life Sciences Inc. (NASDAQ:KZR)
Last: | $0.6464 |
---|---|
Change Percent: | -1.51% |
Open: | $0.6509 |
Close: | $0.6563 |
High: | $0.6598 |
Low: | $0.645 |
Volume: | 47,425 |
Last Trade Date Time: | 06/26/2024 03:00:00 am |
News | Kezar Life Sciences Inc. (NASDAQ:KZR)
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
2024-05-09 17:29:19 ET More on Kezar Life Sciences Seeking Alpha’s Quant Rating on Kezar Life Sciences Historical earnings data for Kezar Life Sciences Financial information for Kezar Life Sciences Read the full article on Seeking Alpha For fur...
Message Board Posts | Kezar Life Sciences Inc. (NASDAQ:KZR)
Subject | By | Source | When |
---|---|---|---|
As an update . After doing more research | Whalatane | investorshub | 04/04/2023 6:11:19 PM |
Yahoo finance today reporting market cap at $271.2 | Whalatane | investorshub | 03/16/2023 5:27:34 PM |
Well I obviously should have waited until after | Whalatane | investorshub | 03/16/2023 2:38:49 PM |
Buying at these levels . Their LN | Whalatane | investorshub | 03/13/2023 3:36:07 PM |
For the record ...not that anyone reads this | Whalatane | investorshub | 01/19/2023 10:31:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...